Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia

Assistance Publique - Hôpitaux de Paris236 enrolled

Overview

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) : * Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP * Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP * Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP * Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP * Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

Study Type

OBSERVATIONAL

Enrollment

236

Conditions

Preeclampsia

Interventions

A collection of maternal plasma and serumBIOLOGICAL

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age from 18 to 50 years old * Singleton pregnancies between 20 and 41 weeks of gestation * Preeclampsia * Normal pregnancy Exclusion Criteria: * Age\<18 * Infectious disease: HIV, HBV or HCV * Multiple pregnancies * Opposition of the patient

Locations (1)

Hopital Cochin

Paris, France

Outcomes

Primary Outcomes

ratio sFlt-1/PlGF

measurement of of sFlT-1 and PlGF

Time frame: Day 0

Secondary Outcomes

Kinetics of these ratios sFlt-1/PlGF during pregnancy

measurement of of sFlT-1 and PlGF at many times

Time frame: until 5 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.